title: In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. The influence of reagents and standards.
abstract: Factor IX (FIX) recovery and half-life was measured in ten hemophilia B patients under standardized conditions. Each patient received a steam-treated high-purity factor IX concentrate at a dose of 19-39 U/kg body weight. FIX activity was determined using a one-stage assay, which was calibrated against the international concentrate standard (reagents from Immuno, Heidelberg). The in vivo recovery ranged from 24% to 53% (mean value 37.7%) and the half-disappearance time (HDT) from 8-30 h (mean 16.7 h). In four of the ten patients, the distribution and elimination half-lives were estimated and ranged from 0.3 h to 3.9 h (mean 1.4 h) and from 28.6 h to 39.7 h (mean 33.1 h), respectively. In six patients FIX was redetermined using a different FIX deficient plasma and a plasma standard (reagents from Merz & Dade, Munich, FRG). Recoveries and HDT based on the results obtained with this method were significantly higher (68.2% vs 39.7%; p less than 0.05), and longer (14.8 h vs 10.6 h; p less than 0.05), respectively. FIX activity was also measured by both assay systems in 100 healthy subjects (50 males, 50 females). The reagents from Immuno yielded a mean value of 0.77 U/ml, while the mean FIX activity utilizing standards and reagents from Merz & Dade was 1.11 U/ml (p less than 0.000001). The coefficient of correlation between the FIX activity measurements, as determined in 100 healthy subjects and 6 hemophilia B patients using the different test systems, was r = 0.9 (N = 159; y = 0.08 +/- 1.3* chi; p less than 0.001). Our data suggest that recovery and HDT of factor IX concentrate strongly depend on the assay and calibration conditions and that an international FIX activity plasma standard is urgently required.
authors.affiliation: Abteilung für klinische Hämostaseologie & Transfusionsmedizin, Universität des Saarlandes, Federal Republic of Germany.
authors.forename: M
authors.initials: M
authors.lastname: Köhler
authors.forename: E
authors.initials: E
authors.lastname: Seifried
authors.forename: P
authors.initials: P
authors.lastname: Hellstern
authors.forename: G
authors.initials: G
authors.lastname: Pindur
authors.forename: C
authors.initials: C
authors.lastname: Miyashita
authors.forename: S
authors.initials: S
authors.lastname: Mörsdorf
authors.forename: F
authors.initials: F
authors.lastname: Fasco
authors.forename: E
authors.initials: E
authors.lastname: Wenzel
mesh_terms: D000293:Adolescent; D000328:Adult; D001803:Blood Transfusion / Q000592:standards; D005164:Factor IX / Q000493:pharmacokinetics* / Q000592:standards; D005260:Female; D006207:Half-Life; D002836:Hemophilia B / Q000097:blood*; D006801:Humans; D007202:Indicators and Reagents; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D012015:Reference Standards; D012044:Regression Analysis; D013227:Steam
chemical_list: D007202:Indicators and Reagents; D013227:Steam; D005164:Factor IX